CANCER MEDICINES: WILL PATIENTS GET THE FULL BENEFIT OF THE NEW PRICE CAP?
BIZ MASALA
| SIGNATURE STORY
India has capped trade margins on 137 non-scheduled anti-cancer drugs. The next test is whether the promised savings reach patients.
By Murthy ASR | 18 October 2026
Hero image: editorial illustration. It is not a photograph of
a specific patient, pharmacy or medicine.
India’s
new cancer-drug pricing order is significant—but the headline number is only
the beginning. On 17 October, the National
Pharmaceutical Pricing Authority (NPPA) notified a 30% trade-margin cap
covering 137 identified non-scheduled anti-cancer drugs. Revised prices are
scheduled to take effect on 9 November 2026. The government says maximum retail
prices could fall by as much as 70%, depending on the existing price structure.
That is a possible maximum, not a uniform reduction for every medicine.
What exactly has changed?
India already regulates prices of medicines
on the scheduled list through ceiling prices. The latest order targets
identified non-scheduled anti-cancer formulations—medicines outside that
standard ceiling-price framework. Using the Trade Margin Rationalisation
mechanism under Paragraph 19 of the Drugs (Prices Control) Order, 2013, the
NPPA is limiting the permitted trade margin for the covered products.
In plain language, the regulator is
targeting the mark-up between the price at which a medicine first enters the
supply chain and the price charged downstream. It is not a promise that every
medicine will be 70% cheaper, nor does the order mean that the manufacturer’s
own production price has been cut by 70%. The actual change depends on the
existing price and margin structure of each covered product.
The
policy aims to control the distribution and retail mark-up on the medicines
listed in the notification. Actual invoices and revised price lists will show
how the change flows through each channel.
The medicines—and the patients behind the list
How the pricing rule
moves through the supply chain. Editorial illustration; not a depiction of a
specific company or patient.
The announced list includes medicines used
in modern cancer care, including immunotherapies, targeted therapies and
supportive treatments. News reports identify drugs such as pembrolizumab,
nivolumab, osimertinib, palbociclib, ribociclib, abemaciclib, atezolizumab and
bevacizumab among the medicines covered. These examples are not a substitute
for checking the exact formulation, strength and dosage form in the official
NPPA notification.
Important price-data limitation: The Gazette notification lists 137 drug ingredients/combinations,
not one old and one new price for each ingredient. Prices depend on brand,
strength, dosage form and pack size. The notification uses each formulation’s
March 2026 price-to-stockist/distributor to calculate the permitted MRP. Since
manufacturers must submit revised MRPs after publication and the new prices
take effect on 9 November 2026, a reliable old-versus-new price table for every
formulation is not yet available from the notification itself. We therefore do
not invent or imply a single price per molecule.
|
Example medicine |
Why it matters
(brief, non-exhaustive) |
|
Pembrolizumab /
nivolumab |
Immunotherapy
medicines used in several cancer settings; use depends on diagnosis and
clinical guidance. |
|
Osimertinib |
Targeted therapy used for
certain forms of lung cancer. |
|
Palbociclib /
ribociclib / abemaciclib |
Targeted
medicines used in selected breast-cancer treatment regimens. |
|
Atezolizumab |
Immunotherapy used in
specified cancer indications. |
|
Bevacizumab |
A targeted
medicine used in several cancers, depending on indication. |
|
Pegfilgrastim |
Supportive treatment that
helps reduce the risk of certain low-white-cell complications during cancer
treatment. |
|
Denosumab |
Used in certain
settings involving bone complications; the indication and product formulation
matter. |
The ₹2,500-crore promise needs a receipt
The government has estimated that the
intervention could save patients around ₹2,500 crore annually. That is a policy
estimate, not a measured outcome yet. To judge it fairly, readers need to know
the assumptions behind the estimate: which products and sales volumes were
counted, how existing prices were compared with revised prices, and how much of
the reduction is expected to reach patients who buy medicines through hospitals
rather than retail pharmacies.
The government’s earlier 2019 trade-margin
rationalisation exercise covered 42 anti-cancer drugs. The Centre says that
exercise led to price reductions across 526 brands, with reductions of up to
90%. That history suggests that margin regulation can move prices—but it does
not automatically prove the savings claimed for the expanded 2026 list. The new
measure must be evaluated on its own results.
Illustration
only: the bars demonstrate simple arithmetic, not an actual medicine price, the
effect of this order, or a forecast. Actual reductions will differ by product.
Who must do what before 9 November?
·
Manufacturers must submit
revised prices to the NPPA within seven days of publication of the notification
and publish/disseminate the revised price lists as directed.
·
Retailers and hospitals must
charge the applicable revised prices from the effective date and display the
relevant information, according to the government’s instructions.
·
State drug controllers and the
relevant authorities must monitor compliance. Patients and caregivers should
compare the exact brand, strength, dosage form and pack size—not just the
medicine name.
·
Where medicines are supplied
directly to hospitals, implementation inside hospital procurement and billing
systems will be crucial. A lower maximum retail price is meaningful only if the
bill charged to the patient reflects the applicable rule.
The enforcement question
The practical test:
whether the revised, formulation-specific price appears on pharmacy and
hospital bills. Editorial illustration.
A notification can set the rule; it cannot
by itself guarantee compliance at every counter. The most useful public test
will be a product-by-product comparison of old and revised MRPs, matched
against invoices from pharmacies and hospitals after 9 November. The regulator
should make the revised lists easy to find, explain how patients can report
overcharging, and publish enforcement outcomes in a form the public can
understand.
This is also a supply question. Price
controls need monitoring for availability as well as affordability. The
government has directed manufacturers to maintain supply of the covered
medicines. The follow-up should check whether products remain available and
whether patients are pushed toward different brands or formulations. There is
no basis, at this stage, to claim that shortages will occur; it is a risk to
monitor, not a conclusion.
Why only cancer drugs? The wider pricing debate
The timing is important. Recent Supreme
Court reporting has described the court pressing the government to explain why
action on excessive medicine and medical-device mark-ups should not extend
beyond cancer drugs. That raises a wider question for health policy: should
India rely on targeted interventions for selected products, or develop a more
transparent system for identifying and addressing excessive mark-ups across
essential medicines and devices?
The counterargument also deserves a
hearing. Supply chains cost money to operate, and distribution margins help
medicines reach patients across regions. The policy question is not whether
every margin is improper. It is whether margins are reasonable, transparent,
and consistent with affordable access—especially when patients have limited
choice and treatment cannot easily be postponed.
What patients should check
·
From 9 November 2026, ask the
pharmacy or hospital for the revised price applicable to the exact brand,
strength, dosage form and pack.
·
Keep the bill and compare the
charged price with the displayed revised price list. Do not compare different
strengths or pack sizes as if they were identical.
·
Use the NPPA’s official website
and its Pharma Sahi Daam resources to check price information and complaint
channels.
·
Do not stop, delay or
substitute cancer treatment based on a price headline. Discuss any change of
brand, formulation or treatment with the treating oncologist.
Biz Masala assessment
The
policy deserves attention, but the test is not the announcement—it is the
patient’s bill. The 30% cap creates a regulatory
benchmark for 137 identified non-scheduled anti-cancer drugs. The claimed
savings of up to 70% and ₹2,500 crore annually remain estimates until revised
prices are implemented and measured. Biz Masala will be able to assess the
policy properly by comparing official price lists, real invoices, product
availability and enforcement results after 9 November.
Sources and reporting notes
·
Government of India, Press
Information Bureau, 17 October 2026 — Trade Margin Rationalisation on 137
Anti-Cancer Drugs
https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2324743&lang=1®=3
·
National Pharmaceutical Pricing
Authority — official notifications and price resources
https://www.nppa.gov.in/en
·
Government of India, PIB, 8
October 2026 — Government Expands Cancer Medicine Price Controls; Cancer
Patients Expected to Save ₹2,500 Crore Annually
https://www.pib.gov.in/PressReleasePage.aspx?PRID=2321092&lang=1®=3
·
The Indian Express — Government
caps trade margins on 137 anti-cancer drugs at 30%
https://indianexpress.com/article/india/government-caps-trade-margins-anti-cancer-drugs-10926290/
·
Business Standard — Centre
finalises 30% trade margin cap for 137 non-scheduled cancer drugs
https://www.business-standard.com/amp/industry/news/centre-finalises-30-trade-margin-cap-for-137-non-scheduled-cancer-drugs-126101700942_1.html
·
Financial Express — Supreme
Court presses Centre for wider medicine price controls
https://www.financialexpress.com/india-news/why-only-cancer-drugs-supreme-court-presses-centre-for-wider-medicine-price-controls/4359522/
Editorial
note: This article distinguishes official policy facts from government
estimates and media-reported examples. The medicine examples are
non-exhaustive; verify the exact products and formulations against the official
notification before publication. Illustrative charts are not actual price data.
This is not medical advice.
BIZ MASALA
• Business. Economics. Markets.
APPENDIX: ALL 137 DRUGS COVERED BY THE NPPA ORDER
Gazette
notification dated 17 October 2026 • Effective date: 9 November 2026
The list below
reproduces the 137 entries in Table B of the notification, with obvious
spelling variants standardized for readability. Legal coverage should always be
checked against the original Gazette notification and the exact formulation.
The list includes individual drugs and specified combinations.
Why
there are no old/new prices beside each drug: Table
B is a list of drug names, not a brand-wise price schedule. One ingredient can
appear in multiple brands, strengths, dosage forms and pack sizes, each with
its own MRP. The Gazette’s formula uses the relevant March 2026 price to
stockist/distributor (PTS/PTD), with trade margin capped at 30% and applicable
GST. Revised formulation-level MRPs must be taken from manufacturer price
lists/NPPA records; they should not be guessed from the molecule name.
|
No. / drug name |
Old MRP |
Revised MRP |
|
1. Abemaciclib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
2. Abiraterone
acetate |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
3. Acalabrutinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
4. Afatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
5. Alectinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
6. Alpelisib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
7. Amivantamab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
8. Anastrozole |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
9. Apalutamide |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
10. Asciminib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
11. Atezolizumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
12. Avelumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
13. Axitinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
14. Azacitidine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
15. Belantamab
mafodotin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
16. Bevacizumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
17. Bosutinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
18. Brentuximab
vedotin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
19. Brigatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
20. Busulfan |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
21. Cabazitaxel |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
22. Cabozantinib
(S)-maleate |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
23. Capmatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
24. Carfilzomib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
25. Carmustine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
26. Ceritinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
27. Cetuximab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
28. Cladribine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
29. Clofarabine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
30. Crizotinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
31. Cytarabine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
32. Dabrafenib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
33. Dacomitinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
34. Daratumumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
35. Darolutamide |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
36. Dasatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
37. Datopotamab
deruxtecan |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
38. Decitabine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
39. Degarelix |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
40. Denosumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
41. Dostarlimab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
42. Durvalumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
43. Elranatamab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
44. Enfortumab
vedotin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
45. Entrectinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
46. Enzalutamide |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
47. Epirubicin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
48. Erdafitinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
49. Eribulin
mesylate |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
50. Erlotinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
51. Estramustine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
52. Everolimus |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
53. Exemestane |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
54. Fludarabine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
55. Fulvestrant |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
56. Gilteritinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
57. Goserelin
acetate |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
58. Ibritumomab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
59. Ibrutinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
60. Idelalisib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
61. Ifosfamide +
mesna |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
62. Nivolumab +
relatlimab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
63. Pegylated
liposomal irinotecan |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
64. Inotuzumab
ozogamicin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
65. Interferon
alfa-2b |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
66. Ipilimumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
67. Ivosidenib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
68. Lapatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
69. Lazertinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
70. Lenvatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
71. Lomustine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
72. Lorlatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
73. Lymphoseek
kit |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
74. Megestrol |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
75. Midostaurin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
76. Mirvetuximab
soravtansine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
77. Mitomycin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
78. Mitoxantrone |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
79. Nelarabine |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
80. Netupitant |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
81. Nilotinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
82. Nimotuzumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
83. Nintedanib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
84. Niraparib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
85. Nivolumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
86. Obinutuzumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
87. Ofatumumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
88. Olaparib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
89. Osimertinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
90. Palbociclib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
91. Panitumumab
(Vectibix) |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
92. Pazopanib
(as hydrochloride) |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
93. Pegaspargase |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
94.
Pegfilgrastim |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
95. Pegylated
interferon alfa-2b |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
96.
Pembrolizumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
97. Pemetrexed |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
98. Pertuzumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
99. Pertuzumab +
trastuzumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
100. Plerixafor |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
101. Polatuzumab
vedotin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
102.
Pomalidomide |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
103. Ramucirumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
104. Regorafenib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
105. Relugolix |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
106. Ribociclib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
107. Rucaparib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
108. Ruxolitinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
109.
Selpercatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
110. Selumetinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
111. Serplulimab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
112. Sotorasib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
113. Sunitinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
114. Talquetamab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
115. Teclistamab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
116. Tegafur +
uracil |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
117. Tegafur +
gimeracil + oteracil |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
118.
Temsirolimus |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
119. Tepotinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
120. Thiotepa |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
121.
Tislelizumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
122. Tocilizumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
123. Topotecan |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
124. Toripalimab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
125. Trabectedin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
126. Trametinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
127.
Tremelimumab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
128. Treosulfan |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
129.
Trifluridine + tipiracil |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
130. Triptorelin |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
131. Tucatinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
132. Vemurafenib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
133. Venetoclax |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
134. Vinorelbine
tartrate |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
135. Vorasidenib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
136.
Zanubrutinib |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
|
137.
Zolbetuximab |
Formulation-specific;
not stated in Table B |
To be verified
from revised brand/pack price list |
Price calculation in the notification: The order specifies a maximum 30% trade margin and a
formulation-level MRP calculation based on the March 2026 PTS/PTD, plus
applicable GST. A 30% trade margin on MRP corresponds to a 42.86% mark-up on
PTS/PTD before GST; it does not mean every medicine’s MRP will fall by exactly
30%. The actual reduction depends on the earlier price and distribution
structure.
Primary source: Government of India, Gazette/PIB,
“Trade Margin Rationalisation on 137 Anti-Cancer Drugs”, 17 October 2026.
Official NPPA notification listing: https://www.nppa.gov.in/en/view_more
Government summary:
https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2324743&lang=1®=3
BIZ MASALA
• Business. Economics. Markets.
Comments
Post a Comment